Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix reported fiscal Q3 2026 revenue of $673.1 million, up from $7.9 million a year earlier, largely reflecting $653.2 million of Roche license revenue and a $10 million Sanofi milestone. Net income was $549.8 million, or $4.73 per diluted share, versus a net loss of $86.4 million a year earlier; cash, cash equivalents and marketable securities totaled $1.1 billion, with runway into the second half of 2029. The company initiated the Phase 3 DAYBreak CLL-306 trial of bexobrutideg and advanced NX-1607 into Phase 1b expansion cohorts, while discontinuing further clinical development of NX-2127.

Analysis

NRIX’s financing risk has fallen, but its earnings signal has not improved in proportion to the reported profit: the Roche license revenue is transaction-driven, not a recurring run rate. The investable question is whether the cash enables value-creating development without a corresponding rise in Nurix’s 40% share of bexobrutideg costs. The agreement also shifts part of the funding burden to Roche while leaving Nurix with meaningful U.S. execution and commercial exposure.

The main upside is clinical and long-dated: early activity creates a credible route to a differentiated position after covalent BTK inhibitor failure, but the Phase 3 comparison with pirtobrutinib must establish comparative benefit on the trial’s endpoints. Early response rates are not a substitute for randomized PFS or durable safety data. With NX-2127 discontinued, portfolio value is more concentrated in bexobrutideg; NX-1607 remains an early-stage, high-variance option. The reported cash runway reduces near-term dilution risk, not clinical risk.

Near term, the accounting-driven EPS headline may attract momentum but is a poor basis for extrapolation. Over 1–3 months, enrollment pace and any additional pivotal or combination updates matter more; definitive Phase 3 value realization is likely a multi-year question. A contrarian risk is that investors price the cash and early efficacy as if commercial success were substantially de-risked. The thesis weakens on slower enrollment, adverse safety signals, or evidence that randomized efficacy does not support superiority; verify valuation, post-deal cash burn, and Nurix’s projected collaboration obligations before sizing.

Key Decisions for Investors

• Do not annualize the quarter’s GAAP earnings or buy NRIX solely on the reported EPS. Treat the Roche license revenue as nonrecurring and track cash burn and development spending separately.
• Keep NRIX on a catalyst watch rather than initiate a valuation-insensitive position. Reassess after confirming current enterprise value, cash net of obligations, and the planned cost profile of the 40% development share; consider a staged position only if the valuation does not already capitalize clinical success.
• For any NRIX exposure, size as a clinical-event risk: monitor DAYBreak CLL-306 enrollment, independent-review response and PFS updates, and tolerability. Reduce the thesis if enrollment slips materially or emerging safety/efficacy data undermine differentiation versus pirtobrutinib.
• No material trade is indicated in GILD, SNY, or PFE from the cited milestones alone: collaboration payments and research extensions are not, on this information, evidence of a meaningful change to their consolidated earnings outlook.